Johnson Financial Group Inc. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 34.1% in the second quarter, according to its most recent filing with the SEC. The firm owned 46,280 shares of the biopharmaceutical company’s stock after acquiring an additional 11,768 shares during the period. Johnson Financial Group Inc.’s holdings in Gilead Sciences were worth $3,276,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC boosted its stake in Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. American Beacon Advisors Inc. acquired a new position in Gilead Sciences in the 1st quarter worth $143,000. Sterling Investment Advisors Ltd. acquired a new position in Gilead Sciences in the 2nd quarter worth $184,000. Finally, Truepoint Inc. acquired a new position in Gilead Sciences in the 2nd quarter worth $204,000. 74.62% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.41 on Friday. The stock has a market cap of $93,803.18, a PE ratio of 7.50, a PEG ratio of -1.20 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue was down 13.2% on a year-over-year basis. During the same period last year, the company earned $2.75 earnings per share. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.87%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.
GILD has been the topic of several analyst reports. BMO Capital Markets reissued a “hold” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target on the stock in a research report on Wednesday, September 6th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $84.87.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the sale, the chief financial officer now directly owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 666,819 shares of company stock worth $52,303,086. 1.30% of the stock is owned by corporate insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.